One Drug, Two Diseases, and a Biologic Already Working for One of Them
For one patient, a single approved biologic solving two diseases at once is close to a clean answer. For the next, the same logic runs straight into a working drug nobody wants to risk losing.
He has worked the same warehouse floor for eight years, and lately both his skin and his breathing get noticeably worse by the end of a shift — a pattern that, on questioning, turns out to reflect two separate but simultaneously undercontrolled diseases rather than one aggravating the other. His moderate atopic dermatitis has responded only partially to topical steroids, and his moderate persistent asthma, despite an inhaled steroid/LABA combination, has needed two courses of oral steroids for exacerbations this year alone.
The eczema indication is unconditional; the asthma one is not. Dupilumab is approved as add-on maintenance only for moderate-to-severe asthma characterized by an eosinophilic phenotype or for oral-corticosteroid-dependent asthma, and two exacerbation bursts a year is not corticosteroid dependence — that phrase means maintenance oral steroids, which he has never taken. So the whole asthma half of the argument rests on the first clause, and therefore on numbers nobody had ordered until this visit: blood eosinophils 420 and a FeNO of 38 put him inside the type-2-high group where LIBERTY ASTHMA QUEST found dupilumab's exacerbation benefit concentrated, rather than in the broader moderate-asthma population where it is not. Had those come back low, the dual-indication argument would have collapsed into an ordinary eczema prescription with a coincidental second diagnosis.
He is otherwise healthy, a nonsmoker, with no cardiac or other chronic disease, and his allergy workup years ago confirmed elevated total IgE and positive dust-mite sensitization consistent with an atopic phenotype driving both conditions rather than two coincidentally unrelated diagnoses. He mentioned that he has already asked his shift supervisor about being moved to a lower-dust area of the warehouse, a request that was denied for scheduling reasons, which makes controlling both diseases pharmacologically more important precisely because the environmental trigger itself isn't going away.
His two oral steroid courses this year both followed the same pattern — a bad week on the floor, a weekend spent mostly on the couch recovering, then back to a baseline that was never actually good to begin with, just tolerable enough not to complain about out loud until his wife pushed him to get it properly evaluated. That pattern, more than any single number on his chart, is what convinced the team a single well-matched drug addressing both diseases at once was worth pursuing rather than incrementally adjusting either regimen in isolation.
Both his eczema and his asthma are undercontrolled right now, independently, and with eosinophils at 420 and FeNO at 38 he qualifies under the asthma label's eosinophilic-phenotype clause — which is the clause that matters, because he isn't oral-steroid-dependent and two rescue courses don't make him so. I don't see a reason to manage these as two separate problems needing two separate drugs when one already-indicated option covers both active diseases.
I agree here, with one thing said out loud rather than assumed. His control score and exacerbation history support escalating asthma therapy regardless of the skin question, and QUEST's benefit ran with baseline eosinophils and FeNO, so his numbers are what make this a dual-indication case rather than an eczema drug we're hoping helps his chest. If he'd come back type-2-low I'd be arguing the other way. VENTURE is the trial for steroid-dependent patients and it isn't his situation, which is worth naming so nobody cites it later as though it were.
Agreed, without real disagreement: start dupilumab, continue his inhaled combination controller, and follow both his eczema and his asthma control score at the next visit.
Both voices noted this was close to the least contested decision either had made this month — two active, undercontrolled diseases and one drug with independent trial evidence in each was not a case requiring extended debate.
She has run marathons for most of her adult life, and two years ago that had become impossible — her severe eosinophilic asthma was landing her in urgent care every few months until mepolizumab brought it under real control, control good enough that she finished a half-marathon last spring for the first time in years. Her atopic dermatitis, meanwhile, has never been more than moderately controlled by topical therapy alone, and it has gradually worsened over the same two years her asthma has gotten better.
The obvious pull is toward the same logic that resolved Patient A's case cleanly: one drug, two diseases. But her asthma isn't undercontrolled — it is stable, on a biologic chosen specifically for her eosinophilic phenotype, and switching to dupilumab means gambling a hard-won, currently-working control on a different drug's asthma efficacy, which itself concentrates in patients with elevated type-2 biomarkers she hasn't recently had rechecked. Being eosinophilic enough to qualify for mepolizumab is not the same claim as being the kind of type-2-high patient dupilumab's own asthma trials predict will respond.
She has no other chronic medical conditions besides the two atopic diseases under discussion, has never smoked, and has tolerated mepolizumab without any adverse effects across two full years of injections. She was candid that the prospect of switching biologics frightens her more than the eczema itself does — not because she doubts the reasoning behind it, but because she remembers vividly what her life looked like before mepolizumab worked, and isn't willing to relive that stretch on the strength of a plausible-sounding argument alone.
Her asthma isn't the problem right now — it's controlled, and controlled asthma isn't a reason to switch biologics. I'd treat her skin with a topical or non-biologic systemic option and leave mepolizumab alone entirely.
If we were starting from scratch with both diseases active, I'd agree dupilumab makes sense. That's not where we are.
I'd add a specific mechanistic caution to that. Dupilumab's asthma efficacy is concentrated in patients with elevated type-2 biomarkers — blood eosinophils, FeNO — which is what QUEST showed. She was selected for mepolizumab on eosinophilic grounds, the DREAM and MENSA criteria, but mepolizumab itself lowers circulating eosinophils, so we don't actually know her current biomarker profile, and being eosinophilic enough for one drug doesn't guarantee response to a mechanistically different one.
Combining two biologics is also a real, largely untested strategy, with cost and coverage problems on top of the safety uncertainty.
I want her AD adequately treated, and I don't think that requires abandoning mepolizumab. If her biomarkers, rechecked off any confounding effect, suggested a strong dupilumab-responder profile, a carefully monitored switch trial with mepolizumab held in reserve would be worth discussing — but that's a real decision for later, not today's default.
For now, escalating her AD treatment with an option that doesn't touch her asthma regimen at all is the lower-risk path.
Agreed: start upadacitinib for her AD, continue mepolizumab unchanged, and check blood eosinophils and FeNO at a stable point well after her next mepolizumab dose to get an unconfounded read on her actual current biomarker profile.
Not agreed and left explicitly open: whether a future dupilumab switch trial should be pursued if her rechecked biomarkers look favorable. The allergist remained skeptical of touching a working regimen under any circumstance; the pulmonologist and dermatologist were open to revisiting it once real biomarker data existed, rather than deciding on a hypothetical today.